Back to top
more

Cassava Sciences, Inc. (SAVA)

(Delayed Data from NSDQ)

$48.58 USD

48.58
2,268,959

-2.30 (-1.58%)

Updated Feb 26, 2021 04:00 PM ET

Pre-Market: $50.80 +2.22 (4.57%) 8:48 AM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (191 out of 253)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull

Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.

Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?

Is (SAVA) Outperforming Other Medical Stocks This Year?

Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $51.22, moving -1.18% from the previous trading session.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

Kevin Cook headshot

Biotech Bonanza: COVID Launches Science at Warp Speed

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More

Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Cassava Sciences' (SAVA) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).

Pacira (PCRX) Gets European Commission Approval for Exparel

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

OptiNose (OPTN) Looks Good: Stock Adds 6.2% in Session

OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU

Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance

Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.

What's in the Cards for Cassava (SAVA) This Earnings Season?

Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.

Moving Average Crossover Alert: Cassava Sciences

Cassava Sciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Kinjel Shah headshot

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

There is uncertainty about the impact of the coronavirus pandemic on the Zacks Medical-Drugs industry. However, with demand trends expected to improve in the second half of 2020, SAVA, KMPH, NERV, ALDX may prove to be good additions to the portfolio.

Cassava Sciences' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Cassava Sciences.

Sweta Killa headshot

Healthcare ETFs, Stocks That Gained Double Digits Last Week

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%

Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% Higher

Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.